Search for: "Gottlieb v. Gottlieb" Results 361 - 380 of 418
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Mar 2018, 6:23 am
Wang (Harvard Business School), on Monday, March 19, 2018 Tags: Equity-based compensation, Executive Compensation, Inequality, Institutional Investors, Long-Term value, Payouts, Public interest, R&D, Repurchases, Securities regulation, Shareholder value Risk Management and the Board of Directors Posted by Martin Lipton, Sabastian V. [read post]
12 Jun 2019, 11:56 am by Jeff Margulies (US)
In a statement, FDA Commission Scott Gottlieb, M.D., stated: We’ve taken this position because we too have carefully reviewed the most current research on coffee and cancer and it does not support a cancer warning for coffee. [read post]
27 Apr 2018, 6:01 am
Posted by Vishal Gupta, Sandra Mortal, and Xiaohu Guo (University of Alabama), on Saturday, April 21, 2018 Tags: Compensation ratios, Diversity, Executive Compensation, Management Corporate Governance Deviance Posted by Ruth V. [read post]
14 Sep 2018, 6:12 am
(Delaware Supreme Court and Harvard Law School), on Wednesday, September 12, 2018 Tags: Campaign finance, Citizens United v. [read post]
12 Apr 2019, 6:20 am
Securities and Exchange Commission, on Wednesday, April 10, 2019 Tags: Accountability, No-action letters, Public interest, SEC, Securities regulation, Transparency Executive Long-Term Incentive Plans Posted by Joseph Kieffer, Equilar Inc., on Thursday, April 11, 2019 Tags: Compensation ratios, Equity-based compensation, Executive Compensation, Incentives, Management, Pay for performance The SEC v. [read post]
2 Nov 2015, 3:09 am by Peter Mahler
Add to the growing list of equity-driven rulings for these contract-centric creatures of statute an unpublished decision last week by a New Jersey intermediate appellate court in All Saints University of Medicine Aruba v Chilana, No. [read post]
15 Nov 2019, 6:17 am
Preston and Michael James, Cleary Gottlieb Steen & Hamilton LLP, on Sunday, November 10, 2019 Tags: Asset management, Capital markets, ESG, Impact investing, International governance, Shareholder activism Understanding the Impact of America’s Clampdown on Proxy Advisors Posted by Amy Freedman, Michael Fein, and Ian Robertson, Kingsdale Advisors, on Sunday, November 10, 2019 Tags: Boards of Directors, Institutional… [read post]
13 Oct 2019, 1:07 pm by Ron Friedmann
I hope we learn more here about how data can help avoid lawsuits or at least reduce the expense of dealing with them  Speakers:  James Lee, CEO/Co-Founder,  LegalMationPatrick V. [read post]
20 Sep 2022, 1:44 pm by Kevin LaCroix
  In the Court’s June 30, 2022 opinion by Chief Justice John Roberts in West Virginia v. [read post]
14 Jan 2022, 5:57 am
Lund (University of Southern California), on Tuesday, January 11, 2022 Tags: Citizens United v. [read post]
12 Jun 2019, 11:56 am by Jeff Margulies (US)
In a statement, FDA Commission Scott Gottlieb, M.D., stated: We’ve taken this position because we too have carefully reviewed the most current research on coffee and cancer and it does not support a cancer warning for coffee. [read post]
24 Sep 2018, 8:19 pm by Georgina Hey (AU)
As a result, producers of plant-based dairy alternative beverages have been freely using the term “milk” to describe their products for decades, despite the fact that, as FDA Commissioner Scott Gottlieb quipped at a summit in July, “an almond doesn’t lactate”. [read post]
1 Feb 2019, 6:05 am
Barry, Cleary Gottlieb Steen & Hamilton LLP, on Sunday, January 27, 2019 Tags: Equity-based compensation, Executive Compensation, Incentives, Institutional Investors, institutional Shareholder Services Inc. [read post]
7 Jun 2018, 9:30 pm by Bobby Chen
FDA Commissioner Scott Gottlieb stated that the “warning letters go right to the source of this illegal activity to let online network operators know that marketing illegal and unapproved opioids directly to U.S. consumers will not go unchallenged by the FDA. [read post]